Comparative Pharmacology
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER versus LIDOPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER versus LIDOPEN.
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER vs LIDOPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is an amide-type local anesthetic that stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting the initiation and conduction of nerve impulses. It exhibits antiarrhythmic activity by suppressing automaticity and conduction in cardiac tissues.
Lidocaine is a sodium channel blocker, stabilizing neuronal membranes by inhibiting the influx of sodium ions, thereby preventing the propagation of action potentials and producing local anesthesia.
Antiarrhythmic: 1-1.5 mg/kg IV bolus, may repeat 0.5-0.75 mg/kg in 5-10 minutes; maximum total 3 mg/kg. Followed by continuous IV infusion 1-4 mg/min. Local anesthesia: maximum 4.5 mg/kg (300 mg) without epinephrine; 7 mg/kg (500 mg) with epinephrine.
Lidocaine 2% topical gel: Apply 1-2 grams (approximately 5-10 cm ribbon) to affected area every 4-6 hours as needed, not to exceed 5 grams per day. For infiltration anesthesia: 1% solution, 0.5-5 mL injected locally; maximum 4.5 mg/kg.
None Documented
None Documented
Terminal elimination half-life: 1.5–2 hours (normal cardiac output and hepatic function). Prolonged in heart failure (up to 10 hours), hepatic disease (up to 5–15 hours), and with continuous infusion (due to saturable metabolism).
1.5–2 hours (terminal); prolonged in hepatic impairment
Renal: ~90% as metabolites (including monoethylglycinexylidide [MEGX] and glycinexylidide [GX]) and ~10% unchanged. Biliary/fecal: <3%.
Renal (10% unchanged; 80% as metabolites), biliary/fecal (10%)
Category A/B
Category C
Local Anesthetic / Antiarrhythmic (Class Ib)
Local Anesthetic